Recent Advances in the Treatment of Gliomas: The Multimodal Care Therapy

Authors

  • Omar Ibrahim Department of Neurosurgery, Faculty of Medicine, Cairo University, Giza, Egypt https://orcid.org/0000-0002-4901-4978
  • Mohamed A. Hafez Department of Neurosurgery, Faculty of Medicine, Cairo University, Giza, Egypt
  • Helmy Abdel Haleem Department of Neurosurgery, Faculty of Medicine, Cairo University, Giza, Egypt
  • Hussein El Maghraby Department of Neurosurgery, Faculty of Medicine, University of Coventry, Coventry, England

DOI:

https://doi.org/10.3889/oamjms.2021.6229

Keywords:

Glioma, Molecular biology, Awake surgery, 5ALA, Neuronavigation, Extent of resection, Disease-free survival

Abstract

BACKGROUND: Glioblastoma (GBM) is the most devastating primary malignancy of the central nervous system in adults. At present, standard treatment consists of maximal safe surgical resection followed by radiotherapy (60 Gray) with concomitant daily temozolomide chemotherapy. Low-grade gliomas constitute approximately 15% of the nearly primary brain tumors diagnosed in adults each year. Extent of tumor resection has become a strong predictor of patient outcomes, alongside patient age, performance status, tumor histology, and molecular genetics (isocitrate dehydrogenase-1 and 1p/19q codeletion status). Over the past two decades, surgeons have emphasized the importance of maximizing extent of resection and its impact on overall survival, progression-free survival, and time to malignant transformation.

AIM: We aimed to present recent advances in the treatment of gliomas.

METHODS: This is a prospective analysis of 50 patients diagnosed with gliomas which are enrolled in a joint supervision between Kasr Al Aini Hospital, Cairo University, Egypt, and Coventry University Hospitals, England.

RESULTS: The study included 50 patients, 31 males and 19 females, ages ranged from 21 to 75 years (mean age 47.5 years). Gross total resection was achieved in 28 patients (56%). The most common surgical complication in our series was post-operative transient weakness in 4 patients (8%). Mean true survival of low-grade glioma patients was 40.5 months while the mean true survival for anaplastic astrocytoma (Grade 3) patients was 38 months and that of GBM (Grade 4) patients was 18.8 months.

CONCLUSION: Despite persistent limitations in the quality of data, mounting evidence suggests that more extensive surgical resection is associated with longer life expectancy for both low- and high-grade gliomas.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N Engl J Med [Internet]. 2005 Mar 10 [cited 2020 Jun 30];352(10):987–96. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa043330

Maugeri R, Schiera G, di Liegro CM, Fricano A, Iacopino DG, Di Liegro I. Aquaporins and brain tumors. Vol. 17, International Journal of Molecular Sciences. MDPI AG; 2016. DOI: https://doi.org/10.3390/ijms17071029

Chen B, Wang H, Ge P, Zhao J, Li W, Gu H, et al. Gross total resection of glioma with the intraoperative fluorescence- Guidance of fluorescein sodium. Int J Med Sci [Internet]. 2012 Oct 6 [cited 2020 Jul 1];9(8):708–14. Available from: https://pubmed.ncbi.nlm.nih.gov/23091408/ DOI: https://doi.org/10.7150/ijms.4843

Hollon T, Hervey-Jumper SL, Sagher O, Orringer DA. Advances in the surgical management of low-grade glioma [Internet]. Vol. 25, Seminars in Radiation Oncology. W.B. Saunders; 2015 [cited 2020 Jul 1]. p. 181–8. Available from: /pmc/articles/ PMC4460567/?report=abstract DOI: https://doi.org/10.1016/j.semradonc.2015.02.007

Bondy ML, Scheurer ME, Malmer B, Barnholtz-Sloan JS, Davis FG, Il’yasova D, et al. Brain tumor epidemiology: Consensus from the Brain Tumor Epidemiology Consortium [Internet]. Vol. 113, Cancer. NIH Public Access; 2008 [cited 2020 Jul 1]. p. 1953–68. Available from: /pmc/articles/PMC2861559/?report=abstract DOI: https://doi.org/10.1002/cncr.23741

Duffau H, Capelle L. Preferential brain locations of low-grade gliomas: Comparison with glioblastomas and review of hypothesis. Cancer [Internet]. 2004 Jun 15 [cited 2020 Jul 1];100(12):2622–6. Available from: https://pubmed.ncbi.nlm.nih.gov/15197805/ DOI: https://doi.org/10.1002/cncr.20297

Chang EF, Clark A, Jensen RL, Bernstein M, Guha A, Carrabba G, et al. Multiinstitutional validation of the University of California at San Francisco low-grade glioma prognostic scoring system: Clinical article. J Neurosurg [Internet]. 2009 Aug [cited 2020 Jul 1];111(2):203–10. Available from: https://pubmed.ncbi.nlm.nih.gov/19267536/ DOI: https://doi.org/10.3171/2009.2.JNS081101

Wijnenga MMJ, Mattni T, French PJ, Rutten GJ, Leenstra S, Kloet F, et al. Does early resection of presumed low-grade glioma improve survival? A clinical perspective. J Neurooncol. 2017;

Ramakrishna R, Hebb A, Barber J, Rostomily R, Silbergeld D. Outcomes in Reoperated Low-Grade Gliomas. Neurosurgery [Internet]. 2015 Aug 20 [cited 2020 Jul 1];77(2):175–84. Available from: https://pubmed.ncbi.nlm.nih.gov/25850601/ DOI: https://doi.org/10.1227/NEU.0000000000000753

Buckner JC, Shaw EG, Pugh SL, Chakravarti A, Gilbert MR, Barger GR, et al. Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. N Engl J Med [Internet]. 2016 Apr 7 [cited 2020 Jul 1];374(14):1344–55. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1500925 DOI: https://doi.org/10.1056/NEJMoa1500925

Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, et al. European Association for Neuro- Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas [Internet]. Vol. 18, The Lancet Oncology. Lancet Publishing Group; 2017 [cited 2020 Jul 1]. p. e315–29. Available from: https://pubmed.ncbi.nlm.nih.gov/28483413/ DOI: https://doi.org/10.1016/S1470-2045(17)30194-8

Smith LGF, Nakano I. Fluorescence-guided brain tumor surgery. World Neurosurg [Internet]. 2012 Dec [cited 2020 Jul 1];78(6):559–64. Available from: https://pubmed.ncbi.nlm.nih.gov/23041183/ DOI: https://doi.org/10.1016/j.wneu.2012.10.015

Hadjipanayis CG, Widhalm G, Stummer W. What is the surgical benefit of utilizing 5-aminolevulinic acid for fluorescence-guided surgery of malignant gliomas? Neurosurgery. 2015.

Brown TJ, Bota DA, van Den Bent MJ, Brown PD, Maher E, Aregawi D, et al. Management of low-grade glioma: a systematic review and meta-analysis. Neuro-Oncology Pract [Internet]. 2019 Jul 27 [cited 2020 Jun 30];6(4):249–58. Available from: https://academic.oup.com/nop/article/6/4/249/5076129

Young RM, Jamshidi A, Davis G, Sherman JH. Current trends in the surgical management and treatment of adult glioblastoma [Internet]. Vol. 3, Annals of Translational Medicine. AME Publishing Company; 2015 [cited 2020 Jun 30]. Available from: /pmc/articles/PMC4481356/?report=abstract

Ng WP, Liew BS, Idris Z, Rosman AK. Fluorescence-guided versus conventional surgical resection of high grade glioma: A single-centre, 7-year, comparative effectiveness study. Malaysian J Med Sci. 2017;

Wijnenga MMJ, Mattni T, French PJ, Rutten GJ, Leenstra S, Kloet F, et al. Does early resection of presumed low-grade glioma improve survival? A clinical perspective. J Neurooncol. 2017 May 1;133(1):137–46.

Xia L, Fang C, Chen G, Sun C. Relationship between the extent of resection and the survival of patients with low-grade gliomas: A systematic review and meta-analysis. BMC Cancer [Internet]. 2018 Jan 6 [cited 2020 Jun 30];18(1). Available from: /pmc/articles/PMC5756328/?report=abstract

Schebesch KM, Brawanski A, Hohenberger C, Höhne J. Fluorescein sodium-guided surgery of malignant brain tumors: History, current concepts, and future projects. Turk Neurosurg. 2016;26:185-94. https://doi.org/10.5137/1019-5149.jtn.16952-16.0 PMid:26956810 DOI: https://doi.org/10.5137/1019-5149.JTN.16952-16.0

Schwake M, Stummer W, Suero Molina EJ, Wölfer J. Simultaneous fluorescein sodium and 5-ALA in fluorescence-guided glioma surgery. Acta Neurochir. 2015;157(5):877-9. https://doi.org/10.1007/s00701-015-2401-0 PMid:25820632 DOI: https://doi.org/10.1007/s00701-015-2401-0

Schebesch KM, Proescholdt M, Höhne J, Hohenberger C, Hansen E, Riemenschneider MJ, et al. Sodium fluorescein-guided resection under the YELLOW 560 nm surgical microscope filter in malignant brain tumor surgery a feasibility study. Acta Neurochir (Wien). 2013;155(4):693-9. https://doi.org/10.1007/s00701-013-1643-y PMid:23430234 DOI: https://doi.org/10.1007/s00701-013-1643-y

Neira JA, Ung TH, Sims JS, Malone HR, Chow DS, Samanamud JL, et al. Aggressive resection at the infiltrative margins of glioblastoma facilitated by intraoperative fluorescein guidance. J Neurosurg. 2017;127(1):111-22. https://doi.org/10.3171/2016.7.jns16232 PMid:27715437 DOI: https://doi.org/10.3171/2016.7.JNS16232

Berger MS. The fluorescein-guided technique. Neurosurg Focus. 2014;36(2):E6. PMid:24484259 DOI: https://doi.org/10.3171/2013.11.FOCUS13535

Ferraro N, Barbarite E, Albert TR, Berchmans E, Shah AH, Bregy A, et al. The role of 5-aminolevulinic acid in brain tumor surgery: A systematic review. Neurosurg Rev. 2016;39(4):545-55. https://doi.org/10.1007/s10143-015-0695-2 PMid:26815631 DOI: https://doi.org/10.1007/s10143-015-0695-2

Zhao S, Wu J, Wang C, Liu H, Dong X, Shi C, et al. Intraoperative fluorescence-guided resection of high-grade malignant gliomas using 5-aminolevulinic acid-induced porphyrins: A systematic review and meta-analysis of prospective studies. PLoS One. 2013;8(5):e63682. https://doi.org/10.1371/journal.pone.0063682 PMid:23723993 DOI: https://doi.org/10.1371/journal.pone.0063682

Díez Valle R, Solis ST. To what extent will 5-aminolevulinic acid change the face of malignant glioma surgery?. CNS Oncol. 2015;4(4):265-72. https://doi.org/10.2217/cns.15.10 PMid:26118538 DOI: https://doi.org/10.2217/cns.15.10

Hadjipanayis CG, Widhalm G, Stummer W. What is the surgical benefit of utilizing 5-aminolevulinic acid for fluorescence-guided surgery of malignant gliomas? Neurosurgery. 2015;77(5):663-73. https://doi.org/10.1227/neu.0000000000000929 PMid:26308630 DOI: https://doi.org/10.1227/NEU.0000000000000929

Halani SH, Adamson DC. Clinical utility of 5-aminolevulinic acid HCl to better visualize and more completely remove gliomas. Onco Targets Ther. 2016;9:5629-42. https://doi.org/10.2147/ott.s97030 PMid:27672334 DOI: https://doi.org/10.2147/OTT.S97030

Masubuchi T, Kajimoto Y, Kawabata S, Nonoguchi N, Fujishiro T, Miyatake SI, et al. Experimental study to understand nonspecific protoporphyrin ix fluorescence in brain tissues near tumors after 5-aminolevulinic acid administration. Photomed Laser Surg. 2013;31(9):428-33. https://doi.org/10.1089/pho.2012.3469 PMid:23869519 DOI: https://doi.org/10.1089/pho.2012.3469

Yamada S, Muragaki Y, Maruyama T, Komori T, Okada Y. Role of neurochemical navigation with 5-aminolevulinic acid during intraoperative MRI-guided resection of intracranial malignant gliomas. Clin Neurol Neurosurg. 2015;130:134-9. https://doi.org/10.1016/j.clineuro.2015.01.005 PMid:25615582 DOI: https://doi.org/10.1016/j.clineuro.2015.01.005

Hassan WM. The history of awake craniotomy in hospital universiti Sains Malaysia. Malays J Med Sci. 2013;20(5):67-9. PMid:24643321

Bulsara KR, Johnson J, Villavicencio AT. Improvements in brain tumor surgery: The modern history of awake craniotomies. Neurosurg Focus. 2005;8:e5. https://doi.org/10.3171/foc.2005.18.4.6 PMid:15844868 DOI: https://doi.org/10.3171/foc.2005.18.4.6

Kim SS, McCutcheon IE, Suki D, Weinberg JS, Sawaya R, Lang FF, et al. Awake craniotomy for brain tumors near eloquent cortex: Correlation of intraoperative cortical mapping with neurological outcomes in 309 consecutive patients. Neurosurgery. 2009;64(5):836-45. https://doi.org/10.1227/01.neu.0000342405.80881.81 PMid:19404147 DOI: https://doi.org/10.1227/01.NEU.0000342405.80881.81

Sartorius CJ, Berger MS. Rapid termination of intraoperative stimulation-evoked seizures with application of cold Ringer’s lactate to the cortex. J Neurosurg. 1998;88(2):349-51. https://doi.org/10.3171/jns.1998.88.2.0349 PMid:9452250 DOI: https://doi.org/10.3171/jns.1998.88.2.0349

Eseonu CI, ReFaey K, Garcia O, John A, Quiñones-Hinojosa A, Tripathi P. Awake craniotomy anesthesia: A comparison of the monitored anesthesia care and asleep-awake-asleep techniques. World Neurosurg. 2017;104:679-86. https://doi.org/10.1016/j.wneu.2017.05.053 PMid:28532922 DOI: https://doi.org/10.1016/j.wneu.2017.05.053

Sanai N, Mirzadeh Z, Berger MS. Functional outcome after language mapping for glioma resection. N Engl J Med. 2008;358(1):18-27. https://doi.org/10.1056/nejmoa067819 PMid:18172171 DOI: https://doi.org/10.1056/NEJMoa067819

Laws ER, Taylor WF, Clifton MB, Okazaki H. Neurosurgical management of low-grade astrocytoma of the cerebral hemispheres. J Neurosurg. 1984;61(4):665-73. https://doi.org/10.3171/jns.1984.61.4.0665 PMid:6470776 DOI: https://doi.org/10.3171/jns.1984.61.4.0665

Wu JS, Zhou LF, Tang WJ, Mao Y, Hu J, Song YY, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional neuronavigation: A prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery. 2007;61(5):935-48. https://doi.org/10.1227/01.neu.0000303189.80049.ab PMid:18091270 DOI: https://doi.org/10.1227/01.neu.0000303189.80049.ab

Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998;90(19):1473-9. https://doi.org/10.1093/jnci/90.19.1473 PMid:9776413 DOI: https://doi.org/10.1093/jnci/90.19.1473

Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98-110. https://doi.org/10.3410/f.718384247.793495043 PMid:20129251 DOI: https://doi.org/10.3410/f.718384247.793495043

Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, et al. Maintenance therapy with tumor-Treating fields plus temozolomide vs temozolomide alone for glioblastoma a randomized clinical trial. JAMA. 2015;314(23):2535-43. https://doi.org/10.1001/jama.2015.16669 PMid:26670971 DOI: https://doi.org/10.1001/jama.2015.16669

Brown TJ, Bota DA, van Den Bent MJ, Brown PD, Maher E, Aregawi D, et al. Management of low-grade glioma: A systematic review and meta-analysis. Neuro-Oncol Pract. 2019;6(4):249-58. https://doi.org/10.1093/nop/npy034 PMid:31386075 DOI: https://doi.org/10.1093/nop/npy034

Young RM, Jamshidi A, Davis G, Sherman JH. Current trends in the surgical management and treatment of adult glioblastoma. Ann Transl Med. 2015;3(9):121. PMid:26207249

Ng WP, Liew BS, Idris Z, Rosman AK. Fluorescence-guided versus conventional surgical resection of high grade glioma: A single-centre, 7-year, comparative effectiveness study. Malaysian J Med Sci. 2017;24(2):78-86. PMid:28894407 DOI: https://doi.org/10.21315/mjms2017.24.2.10

Wijnenga MM, Mattni T, French PJ, Rutten GJ, Leenstra S, Kloet F, et al. Does early resection of presumed low-grade glioma improve survival? A clinical perspective. J Neurooncol. 2017;133(1):137-46. https://doi.org/10.1007/s11060-017-2418-8 PMid:28401374 DOI: https://doi.org/10.1007/s11060-017-2418-8

Xia L, Fang C, Chen G, Sun C. Relationship between the extent of resection and the survival of patients with low-grade gliomas: A systematic review and meta-analysis. BMC Cancer. 2018;18(1):48. https://doi.org/10.1186/s12885-017-3909-x PMid:29306321 DOI: https://doi.org/10.1186/s12885-017-3909-x

Downloads

Published

2021-06-02

How to Cite

1.
Ibrahim O, Hafez MA, Haleem HA, El Maghraby H. Recent Advances in the Treatment of Gliomas: The Multimodal Care Therapy. Open Access Maced J Med Sci [Internet]. 2021 Jun. 2 [cited 2024 Mar. 28];9(B):503-8. Available from: https://oamjms.eu/index.php/mjms/article/view/6229